Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
What It Is Class: GLP-1 receptor agonist (incretin mimetic) Concept: Designed to mimic and prolong native GLP-1 signaling involved in glucose-dependent insulin secretion and appetite regulation
The honest bottom line is simply that the evidence isn't there yet
Elife 7 , e36158 (2018)
Source: Evaluate Pharma, World Obesity Federation, Putnam Analysis Q2, 2025 Unmet Needs and Potential Differentiation Levers Despite extraordinary promise, there are still unmet needs that biopharma companies can target to address: GI Tolerability The most common GI adverse events (nausea, vomiting, and diarrhea) often lead to therapy discontinuation
US$ 29.32
US$ 23.56
US$ 28.60
US$ 20.00
US$ 23.16
